Brain Metastases News and Research

RSS

Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients

A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Researchers get closer to creating new blood test that can identify breast cancer brain metastasis

Houston Methodist cancer researchers are now closer to creating a blood test that can identify breast cancer patients who are at increased risk for developing brain metastasis, and also monitor disease progression and response to therapy in real time.

17 Aug 2017

Researchers identify new regulators of brain metastases in lung cancer patients

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

9 Aug 2017

Scientists creating blood test to identify breast cancer patients at risk for brain metastasis

4 Aug 2017

Scientists develop potential new therapy for targeting skin cancer metastases in the brain

Investigators from Brigham and Women's Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain.

10 Jul 2017

Researcher discovers treatment strategy to attack metastatic cancers that have spread to the brain

Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the resistance to HER2- or PI3K-targeted therapies, and a treatment strategy that may overcome treatment resistance.

6 Jun 2017

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

Novartis today announced the US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.

27 May 2017

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017

Combination approach holds potential for treating lung cancer patients

An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.

17 Mar 2017

City of Hope researchers find how HER2-positive breast cancer patients develop brain metastases

Ninety percent of cancer deaths are from cancer spread. Breast cancer patients, for example, typically do not die because cancer returns in their breast, they die because it spreads to other parts of their body. The most dangerous of which is the brain.

2 Mar 2017

Guy's Cancer Centre adds new positioning equipment to enhance patient comfort during radiotherapy treatment

Guy’s and St Thomas’ NHS Foundation Trust has recently opened its new state-of-the-art Cancer Centre to provide radiotherapy, chemotherapy and outpatient services for oncology patients.

1 Feb 2017

Study suggests best sequence of therapies for brain metastases in EGFR mutant lung cancer patients

About 10 percent of lung cancers in the United States and as many as 40 percent in Asia are driven by mutations in the EGFR gene.

25 Jan 2017

Study provides scientific insight into metastatic patterns of EGFR mutated NSCLCs

The discovery of several different subtypes of Non Small Cell Lung Cancer (NSCLC), the most frequent form of lung cancer, has been a major breakthrough in the fight against the leading cause of cancer-related death worldwide.

20 Jan 2017

Researchers identify attractive drug candidate to target glioma tumors

In a paper published today in Cancer Research, researchers: 1) identify a biomarker enzyme associated with aggressive glioma brain tumors, 2) reveal the regulatory mechanism for that enzyme, and 3) demonstrate potent efficacy, using a mouse model of glioma, for a small molecule inhibitor they have developed.

16 Dec 2016

Brain metastasis persists in women with HER2-positive breast cancer despite new targeted therapies

While new targeted treatments developed across the past two decades have led to dramatic survival improvements for women with HER2-positive metastatic breast cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators report that rates of breast cancer brain metastasis for women with this disease have not substantially declined.

7 Dec 2016

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.

28 Sep 2016

Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

SRS reduces likelihood of local recurrence of brain metastases in cancer patients

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.